Abstract: A system for authenticating a medical device is described. The system receives a request from a medical device to access operations or data of an external service provider. The system determines whether the request received from the medical device is valid. When the request is valid, the system generates a token that is customized based on the external service provider identified in the request, and the system transfers the token to medical device, the token enabling the medical device to access the operations or data of the external service provider.

Abstract: A blade for a turbine engine with a wall separating a cooling fluid flow and a hot gas fluid flow and having a heated surface along which the hot gas fluid flow flows and a cooled surface facing the cooling fluid flow. A plurality of cooling holes each having a passage extending between an inlet at the cooled surface and an outlet at the heated surface. The outlet extending between an upstream end and a downstream end with respect to the hot gas fluid flow to define a distance, the passage defining a centerline forming a first angle (?) with the heated surface.

Abstract: A casting core used in the manufacture of a cast engine component for a turbine engine, the cast engine component having a first area, a second area, a fluid passage wall separating the first area and the second area, and a connecting fluid passage extending through the fluid passage wall and interconnecting the first area and the second area. The connecting fluid passage having a turn with a radius (R). The casting core having a first core and a second core. The first core and the second core being defined by a set of geometric characteristics having a first minimum equivalent diameter (D1eqmin) of the first core and a second minimum equivalent diameter (D2eqmin) of the second core. A first flexible geometry factor (FGF1) being equal to: ( D ? 1 eq ? min D ? 2 eq ? min ) ? ( R D ? 2 eq ? min ) .

Abstract: A computer numerically controlled machine may include a source configured to deliver an electromagnetic energy to at least one location within an interior space of the computer-numerically-controlled machine. The electromagnetic energy may have a first range of wavelengths from a visible spectrum. An enclosure defining at least a portion of the interior space of the computer numerically controlled machine may include a transparent portion configured to filter the first range of wavelengths associated with the electromagnetic energy. Moreover, the transparent portion may reflect and/or transmit at least a second range of wavelengths from the visible spectrum not associated with the electromagnetic energy such that the transparent portion of the enclosure exhibits a first color corresponding to the second range of wavelengths.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: A multi-body self-propelled device can include a drive body and a coupled head. The drive body can include a spherical housing and an internal drive system within the spherical housing to propel the multi-body self-propelled device. The drive body can further include a magnet support assembly comprising a rotating portion including a plurality of magnets and a stationary portion comprising one or more magnets. The drive body can further include a yaw motor to drive the rotating portion of the magnet support assembly. The coupled head can include (i) a corresponding rotating portion comprising a plurality of magnets in magnetic interaction, through the spherical housing, with the plurality of magnets of the magnet support assembly, and (ii) a corresponding stationary portion comprising one or more magnets in magnetic interaction with the one or more magnets of the magnet support assembly.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: A multi-body self-propelled device can include a drive body and a coupled head. The drive body can include a spherical housing and an internal drive system within the spherical housing to propel the multi-body self-propelled device. The drive body can further include a magnet support assembly comprising a rotating portion including a plurality of magnets and a stationary portion comprising one or more magnets. The drive body can further include a yaw motor to drive the rotating portion of the magnet support assembly. The coupled head can include (i) a corresponding rotating portion comprising a plurality of magnets in magnetic interaction, through the spherical housing, with the plurality of magnets of the magnet support assembly, and (ii) a corresponding stationary portion comprising one or more magnets in magnetic interaction with the one or more magnets of the magnet support assembly.

Abstract: A multi-body self-propelled device can include a drive body and a coupled head. The drive body can include a spherical housing and an internal drive system within the spherical housing to propel the multi-body self-propelled device. The drive body can further include a magnet holder coupled to the internal drive system to hold a first set of magnetic elements. The coupled head can include a base plate to hold a second set of magnetic elements to create a magnetic interaction with the first set of magnetic elements through the spherical housing. The coupled head can further include a housing structure and a yaw motor that rotates the housing structure independently in relation to the base plate and the drive body.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.